Citations

Clear

941 citation(s) found for "Tan, B".

Phase II efficacy trial of pazopanib in non-clear cell metastatic renal cell carcinoma (PINCR trial).
Costello, Brian A. , Tan, Winston , Leibovich, Bradley C. , Castle, Erik P., Parker, Alexander S. , Dronca, Roxana , Qin, Rui , Ho, Thai H. , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS4606-TPS4606

10.1200/jco.2014.32.15_suppl.tps4606 Get It

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).
Tan, Antoinette R. , Wong, Serena, Warren, Robert, Eng‐Wong, Jennifer , Liu, Minetta C. , Zelnak, Amelia, Shih, Weichung, Ganesan, Shridar , Grana, Generosa , Toppmeyer, Deborah , Lin, Yong , Isaacs, Claudine

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 531-531

10.1200/jco.2014.32.15_suppl.531 Get It

Androgen Mediation—and Antiandrogens Mitigation—of the Epidermal Growth Factor Receptor (EGFR) Inhibitor–Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series
Rowland, Kendrith M. , Atherton, Pamela J., Dakhil, Christopher, Sun, Zhifu , Tan, Angelina D., Schmidt, Lucy J., Nguyen, Phuong L., Breitkopf, Carmen Radecki , Pittelkow, Mark R. , Tindall, Donald J., Menon, Smitha, Jatoi, Aminah , Atherton, Philip J. , Tan, Angelina, Schmidt, Lucy, Tindall, Donald, Jatoi, Aminah , Sun, Zhifu , Le‐Rademacher, Jennifer , Atherton, Pamela J., Atherton, Philip J.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | January 3, 2019 | Volume: 36 | Issue: 6 | Pages: 519-525

10.1177/1049909118819820 | PMID 30602311 Get It

Background: Although 50% to 90% of patients who receive epidermal growth factor receptor (EGFR) inhibitors develop a rash, options for rash prevention or palliation remain limited. This issue is particularly important from a palliative care standpoint because these agents are prescribed only to patients with incurable cancer. Here, we report (1) gene expression profiling of skin biopsies from patients with an EGFR inhibitor–induced rash and (2) a randomized, placebo-controlled feasibility trial with the antiandrogen, spironolactone. Both investigations were undertaken to begin to explore the hypothesis that androgens mediate EGFR inhibitor–induced rash and that antiandrogens palliate it. Methods/Results: First, 4 skin biopsies from patients with EGFR inhibitor–induced rash (3 men and 1 woman) were subject to gene expression microarray profiling. A public data set of normal skin gene expression (Gene Expression Omnibus, GSE22998) served as a reference. Sixty percent of commonly interrogated androgen receptor genes (207 of 308 between the 2 data sets) were differentially expressed ( P < .05) in the rash samples. Second, in a 17-patient double-blinded, placebo-controlled trial with topical spironolactone applied to the face, although the primary feasibility end point was not achieved, patients in the spironolactone arm received more doses of EGFR inhibitor, and anecdotal photographic evidence suggested salutatory effects of spironolactone on rash. Conclusions: Epidermal growth factor receptor inhibitor–induced rash appears to be androgen-mediated; antiandrogen therapy merits further study for rash prevention/palliation.
1166: NIVOLUMAB-INDUCED PNEUMONITIS LEADING TO RESPIRATORY FAILURE
Kwon, Minkyung , Arunthari, Vichaya, Patel, Neal M. , Lee, Augustine S. , Tan, Winston , Young, Paul , Rojas, Carlos A. , Colaco, Brendon

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 560-560

10.1097/01.ccm.0000551911.05745.17 Get It

Hope's Pursuit
Tan, Nicholas Y., Rabatin, Jeffrey T.

Mayo Clinic

Journal of Palliative Medicine | December 18, 2018 | Volume: 21 | Issue: 12 | Pages: 1816-1817

10.1089/jpm.2018.0271 Get It

2289. Accuracy of a Rapid Multiplex PCR Plus a Chromogenic Phenotypic Test Algorithm for the Detection of ESBL and Carbapenemase-Producing Gram Negatives Directly From Blood Cultures
Hon, Pei-Yun, Wee, Sharon , Chia, Jonathan W. Z., Mendis, Shehara M, Izharrudin, Ezlyn, Lin, Ray J H, Chia, Po Ying , Sim, Rees Chin Swee, Teng, Christine B. , Banerjee, Ritu , De, Partha Pratim, Vasoo, Shawn , Lin, Ray J H, Chen, Mark , Chow, Angela , Yoong, Joanne , Lye, David Chien , Tambyah, Paul Anantharajah , Patel, Robin

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S678-S678

10.1093/ofid/ofy210.1942 Get It

1637. Improving Transitions of Care in the Division of Infectious Diseases
Paim, Ana C. , Vijayvargiya, Prakhar , Garrigos, Zerelda Esquer , Tan, Eugene M. , O’Horo, John C.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S44-S45

10.1093/ofid/ofy209.107 Get It

Abstract Background Patients dismissed from the hospital on oral or intravenous antibiotics frequently need follow-up appointments with the Division of Infectious Diseases (ID). Follow-up appointments may be inappropriately scheduled with respect to timing and indication. Suboptimal transitions of care may lead to increased no-shows and ultimately poor patient outcomes. Methods The baseline sample included 102 patients seen by the inpatient ID services at Mayo Clinic’s Rochester Methodist and Saint Mary’s Hospitals between January 1, 2017 and June 30, 2017. Defects in transitions of care were categorized as those pertaining to sign-off templates, sign-off labels, follow-up priority, and timing. The current transfer of care system from our institution is outlined in Figure 1. Results Out of 102 patients, 75 (74%) had at least one defect identified. Root cause analysis revealed multiple factors contributing to this performance gap (Figure 2). Patients often have variable health literacy and social or financial difficulties. There are often multiple ID providers with inadequate time to properly orchestrate follow-up. There are undefined checkpoints and triaging in the department’s scheduling policies. Interventions involved reformatting the ID sign-off template and clarifying the roles of providers in the transitions-of-care process. Analysis after 6 months of implementation revealed improvement of communication among teams, decline in improper sign off by 13% and decrease in antibiotic prescription errors by 2%. Conclusion This study demonstrates that well-designed sign-off templates can help with effective communication of the final treatment plan among providers and possibly improve patient outcomes. The target goal is to reduce the number of improper sign-offs by 50% within 1 year. Disclosures All authors: No reported disclosures.
439. Impact of Pre-Travel Consultation on Clinical Management and Outcomes of Traveler’s Diarrhea
Tan, Eugene M. , Sauver, Jennifer L. St. , Sia, Irene G.

Mayo Clinic

Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S165-S165

10.1093/ofid/ofy210.449 Get It